EMA starts review of Tavneos, a medicine for rare autoimmune diseases GPA and MPA Review prompted by questions regarding data integrity of main study 30 January 2026

EMA publishes information on the volume and outcome of marketing authorisation and post-authorisation applications for the human and veterinary medicines that it evaluates.

Dec 11, 2025 · EMA welcomes the landmark political agreement reached by the European Commission, the European Parliament and the Council of the European Union on the comprehensive reform of the …

Information on the regulation of medicines for human use in the European Union (EU), with a focus on the centralised procedure. The European Medicines Agency (EMA) plays a key role in this procedure.

Emer Cooke, EMA’s Executive Director: 2025 achievements in medicine regulation EMA's Executive Director shares her end-of-year message and takes stock of EMA's work in 2025.

Check EMA's annual reports for insights into our regulatory procedures, activities, and achievements. The reports include an interactive timeline and figures and statistics for easy comprehension.

On this page you can find several ways to contact the European Medicines Agency (EMA) depending on your need for assistance or type of request.

Find information on ongoing and resolved medicine supply shortages assessed by EMA in the table below. The table includes links to individual shortage notices that contain valuable information for …

The European Medicines Agency (EMA) is responsible for the scientific evaluation of centralised marketing authorisation applications (MAA). Once granted by the European Commission, the …

This complements information on medicines published on this website, which only includes medicines that the European Medicines Agency (EMA) evaluates. Some of these registers cover both human …